Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281619153> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4281619153 endingPage "e12604" @default.
- W4281619153 startingPage "e12604" @default.
- W4281619153 abstract "e12604 Background: Neoadjuvant therapy plays an important role in improving the clinical efficacy for patients with stage II-III epidermal growth factor receptor 2 (HER2)-positive breast cancer. Pyrotinib, a new irreversible tyrosine kinase inhibitor (TKI), combined with capecitabine have demonstrated a promising anti-tumour activity in metastatic breast cancer. Here, we conducted a multicenter, randomized, phase II, open-label trial aiming exploring the outcomes of adding pyrotinib to EC-TH neoadjuvant therapy. Methods: Patients aged 18–65 years old with invasive carcinoma, cT1-4N0-3M0 stage, HER2-positive breast cancer were enrolled. Cases were randomly assigned into neoadjuvant therapy with four cycles of epirubicin and cyclophosphamide followed by four cycles of docetaxel (or Paclitaxel for Injection, albumin bound) and trastuzumab (EC-TH), or pyrotinib (400mg day 1-21) combined with EC-TH. Results: 56 patients had completed 8 cycles of neoadjuvant therapy (40 in the treatment group and 16 in the controlled group). 20 patients underwent radical surgery after neoadjuvant therapy. Compared with EC-TH along (37.5%, 3/8), the addition of pyrotinib to EC-TH neoadjuvant chemotherapy (py+EC-TH) significantly increased the pathological complete response (pCR)rate (75%, 9/12) in patients with HER2-positive breast cancer. The objective response rate (ORR) was 87.5% (7/8) vs 100% (12/12) . The most common adverse effects (AEs) in the treatment group was diarrhoea with grade 3 occurred in 3 cases (7.5% 3/40), which most limited in the first treatment cycle. No grade 3 diarrhoea was observed in controlled group. Other AEs including leukopenia occurred similarly in both groups and no cardiovascular dysfunction was observed. Conclusions: Pyrotinib added to EC-TH neoadjuvant therapy significantly increased the pCR rate, suggesting an applicable strategy for HER2-positive breast cancer. Clinical trial information: NCT04290793." @default.
- W4281619153 created "2022-06-13" @default.
- W4281619153 creator A5006546590 @default.
- W4281619153 creator A5010207613 @default.
- W4281619153 creator A5018688163 @default.
- W4281619153 creator A5036780597 @default.
- W4281619153 creator A5053334015 @default.
- W4281619153 creator A5058883051 @default.
- W4281619153 creator A5068376674 @default.
- W4281619153 creator A5082924617 @default.
- W4281619153 creator A5089695678 @default.
- W4281619153 date "2022-06-01" @default.
- W4281619153 modified "2023-09-26" @default.
- W4281619153 title "Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial." @default.
- W4281619153 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e12604" @default.
- W4281619153 hasPublicationYear "2022" @default.
- W4281619153 type Work @default.
- W4281619153 citedByCount "0" @default.
- W4281619153 crossrefType "journal-article" @default.
- W4281619153 hasAuthorship W4281619153A5006546590 @default.
- W4281619153 hasAuthorship W4281619153A5010207613 @default.
- W4281619153 hasAuthorship W4281619153A5018688163 @default.
- W4281619153 hasAuthorship W4281619153A5036780597 @default.
- W4281619153 hasAuthorship W4281619153A5053334015 @default.
- W4281619153 hasAuthorship W4281619153A5058883051 @default.
- W4281619153 hasAuthorship W4281619153A5068376674 @default.
- W4281619153 hasAuthorship W4281619153A5082924617 @default.
- W4281619153 hasAuthorship W4281619153A5089695678 @default.
- W4281619153 hasConcept C121608353 @default.
- W4281619153 hasConcept C126322002 @default.
- W4281619153 hasConcept C143998085 @default.
- W4281619153 hasConcept C168563851 @default.
- W4281619153 hasConcept C197934379 @default.
- W4281619153 hasConcept C2776694085 @default.
- W4281619153 hasConcept C2777176818 @default.
- W4281619153 hasConcept C2777909004 @default.
- W4281619153 hasConcept C2778292576 @default.
- W4281619153 hasConcept C2779786085 @default.
- W4281619153 hasConcept C2780835546 @default.
- W4281619153 hasConcept C2781190966 @default.
- W4281619153 hasConcept C526805850 @default.
- W4281619153 hasConcept C530470458 @default.
- W4281619153 hasConcept C71924100 @default.
- W4281619153 hasConcept C90924648 @default.
- W4281619153 hasConceptScore W4281619153C121608353 @default.
- W4281619153 hasConceptScore W4281619153C126322002 @default.
- W4281619153 hasConceptScore W4281619153C143998085 @default.
- W4281619153 hasConceptScore W4281619153C168563851 @default.
- W4281619153 hasConceptScore W4281619153C197934379 @default.
- W4281619153 hasConceptScore W4281619153C2776694085 @default.
- W4281619153 hasConceptScore W4281619153C2777176818 @default.
- W4281619153 hasConceptScore W4281619153C2777909004 @default.
- W4281619153 hasConceptScore W4281619153C2778292576 @default.
- W4281619153 hasConceptScore W4281619153C2779786085 @default.
- W4281619153 hasConceptScore W4281619153C2780835546 @default.
- W4281619153 hasConceptScore W4281619153C2781190966 @default.
- W4281619153 hasConceptScore W4281619153C526805850 @default.
- W4281619153 hasConceptScore W4281619153C530470458 @default.
- W4281619153 hasConceptScore W4281619153C71924100 @default.
- W4281619153 hasConceptScore W4281619153C90924648 @default.
- W4281619153 hasIssue "16_suppl" @default.
- W4281619153 hasLocation W42816191531 @default.
- W4281619153 hasOpenAccess W4281619153 @default.
- W4281619153 hasPrimaryLocation W42816191531 @default.
- W4281619153 hasRelatedWork W1979057726 @default.
- W4281619153 hasRelatedWork W2026040915 @default.
- W4281619153 hasRelatedWork W2069548442 @default.
- W4281619153 hasRelatedWork W2111633398 @default.
- W4281619153 hasRelatedWork W2293095450 @default.
- W4281619153 hasRelatedWork W2340306832 @default.
- W4281619153 hasRelatedWork W2376759146 @default.
- W4281619153 hasRelatedWork W3118368214 @default.
- W4281619153 hasRelatedWork W4225868084 @default.
- W4281619153 hasRelatedWork W4206891336 @default.
- W4281619153 hasVolume "40" @default.
- W4281619153 isParatext "false" @default.
- W4281619153 isRetracted "false" @default.
- W4281619153 workType "article" @default.